Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
-
Italy's Paris claims first win of season in World Cup downhill finale
-
In Finland, divers learn to explore icy polar waters
-
Dortmund extend injured captain Can's contract
-
Iranians mark Eid as Trump mulls winding down war
-
Matisse's last years cut out -- but not pasted -- at Paris expo
-
BTS fans take over central Seoul for K-pop kings' comeback
-
Star jockey McDonald becomes horse racing's most prolific Group 1 winner
-
Israel strikes Tehran, Beirut as Trump mulls 'winding down' war
-
Pistons top Warriors to clinch NBA playoff berth
-
Tickets to toothbrushes: BTS's money-making machine
-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
-
Chuck Norris, roundhouse-kicking action star, dead at 86
-
US newcomer Anthony crowned world indoor sprint king
-
Trump rules out Iran truce as more Marines head to Middle East
-
Costa Rican ex-security minister extradited to US for drug trafficking
-
Trump slams NATO 'cowards' as more Marines head to Middle East
-
Gulf's decades-long strategy of sporting investment rocked by Mideast war
-
Souped-up VPNs play 'cat and mouse' game with Iran censors
-
Attacked Russian tanker drifting toward Libya: Italian authorities
-
Coroner 'not satisfied' boxer Hatton intended to take own life
-
Stocks drop, as oil rises as Mideast war persists
-
Vanishing glacier on Germany's highest peak prompts ski lift demolition
-
Chuck Norris, roundhouse-kicking action star, dead at 86: family
-
Supreme leader says Iran dealt enemies 'dizzying blow'
-
Audi team principal Wheatley in shock exit after two races
-
Spurs boss Tudor hopes for 'nice surprises' in relegation fight
-
Arsenal must prove they are winners in League Cup final, says Arteta
-
Record-breaking heat wave grips western US
-
Liverpool showdown brings back 'beautiful memories' for PSG coach Luis Enrique
-
IRA bomb victims drop civil court claim against Gerry Adams
-
Ntamack returns for Toulouse to face France rival Jalibert
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 12:01 Eastern Time on Monday, December 1, 2025. The name change closely aligns the Company's business following its acquisition of 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and controls platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources including battery energy storage systems. In connection with the name change, the Company will change its ticker symbol to "GRDX". The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on December 1, 2025.
"This marks the beginning of a new chapter for the business," said Jason Sawyer, Interim Chief Executive Officer of GridAI Technologies Corp. "Our mission is to enhance grid-edge intelligence using AI, machine learning and edge analytics by orchestrating supply and demand in real time, creating a more reliable, resilient, and transactive grid -now supported with our public-company platform - and this name change reflects that commitment."
The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.
Further updates will be provided via regular press releases and regulatory filings.
About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics, Inc. is a publicly listed company on Nasdaq. The Company is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, the Company intends to continue these prior operations and to also operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company's SEC filings. The Company undertakes no obligation to update forward-looking statements.
Investor & Media Contacts:
Entero Investor Relations
[email protected]
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
A.Malone--AMWN